453 related articles for article (PubMed ID: 17970704)
1. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
2. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
3. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
[TBL] [Abstract][Full Text] [Related]
4. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
5. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
6. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
7. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
8. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.
Kulcsar-Jakab E; Petho Z; Pap Z; Kalina E; Foldesi R; Balogh A; Antal-Szalmas P; Bhattoa HP
BMC Musculoskelet Disord; 2015 Aug; 16():227. PubMed ID: 26311162
[TBL] [Abstract][Full Text] [Related]
9. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
[TBL] [Abstract][Full Text] [Related]
10. The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure.
Fahrleitner-Pammer A; Dobnig H; Dimai HP; Holzer H; Benesch T; Borchhardt K; Cejka D; Haas M
Clin Nephrol; 2009 Jun; 71(6):652-9. PubMed ID: 19473634
[TBL] [Abstract][Full Text] [Related]
11. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
12. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
14. Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia.
Honsawek S; Chaiwatanarat T; Vejchapipat P; Chongsrisawat V; Thawornsuk N; Poovorawan Y
Pediatr Surg Int; 2009 Mar; 25(3):261-7. PubMed ID: 19184056
[TBL] [Abstract][Full Text] [Related]
15. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.
Angelopoulos NG; Goula A; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Malaktari S; Athanasiou V; Tolis G
J Bone Miner Metab; 2007; 25(1):60-7. PubMed ID: 17187195
[TBL] [Abstract][Full Text] [Related]
16. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
[TBL] [Abstract][Full Text] [Related]
17. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.
Fernández-García D; Muñoz-Torres M; Mezquita-Raya P; de la Higuera M; Alonso G; Reyes-García R; Ochoa AS; Ruiz-Requena ME; Luna JD; Escobar-Jiménez F
J Endocrinol Invest; 2008 May; 31(5):416-21. PubMed ID: 18560259
[TBL] [Abstract][Full Text] [Related]
18. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
Zupan J; Mencej-Bedrac S; Jurković-Mlakar S; Prezelj J; Marc J
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):102-6. PubMed ID: 19896533
[TBL] [Abstract][Full Text] [Related]
19. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
[TBL] [Abstract][Full Text] [Related]
20. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
Stern A; Laughlin GA; Bergstrom J; Barrett-Connor E
Eur J Endocrinol; 2007 May; 156(5):555-62. PubMed ID: 17468191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
